Chemical Structure (Toviaz 01)
Toviaz Tablet, Film Coated, Extended Release
Product Images NDC 0069-0244
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Toviaz (NDC 0069-0244). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Toviaz 02)
The text describes a figure (Figure 1) that shows the mean change from baseline in the number of micturitions per 24 hours in a study (Study 1). The study examined the effect of a drug called Toviaz (in two different doses) compared to a placebo. The data are presented in three different time points: 2, 8, and 12 weeks. The number of participants in each group (Placebo, Toviaz 4mg, and Toviaz 8mg) is provided.*
Figure 2 (Toviaz 03)
The text describes a figure with three lines representing the mean change from baseline for different treatments on urge incontinence episodes per 24 hours over a period of 12 weeks. The treatments are a placebo, Toviazdmg, and Toviaz8mg. There are 211 participants in the placebo group, 199 in the Toviazdmg group, and 223 in the Toviaz8mg group.*
Figure 3 (Toviaz 04)
The text describes a figure showing the change in the number of micturitions (urination) per day over a period of 12 weeks in a study that had three groups: a placebo group with 266 participants, a group taking Toviaz4mg with 267 participants, and a group taking Toviaz8mg with 267 participants. The figure shows the mean change from baseline.*
Figure 4 (Toviaz 05)
The text describes a graph showing the mean change in urge incontinence episodes per 24 hours over the course of a study. The study had four different groups, including a placebo group and three groups taking different doses of the medication Toviaz. The graph displays results from week 0, week 2, week 8, and week 12 of the study.*
Logo (Toviaz 06)
Pfizer Labs, a division of Pfizer Inc. located in New York City (zip code 10017), distributes products related to healthcare.*
Logo (Toviaz 07)
This is a label indicating that the product is distributed by Pfizer Labs, a division of Pfizer Inc., based in New York, NY 10017.*
Principal Display Panel (4 mg Tablet Bottle Label)
This is a description of a medication called Toviaz, which is distributed by Pfizer Labs. The medication comes in the form of extended-release tablets and is prescribed for use in treating urinary disorders. The tablets should be stored between 15°C to 30°C and protected from moisture. The prescription is available in 4mg and is only available with a prescription. The text includes the medicine's National Drug Code (NDC) number and manufacturing information.*
Principal Display Panel (8 mg Tablet Bottle Label)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
